We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-3.23%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.84B
AUM Growth
-$282M
Cap. Flow
-$43.3M
Cap. Flow %
-0.89%
Top 10 Hldgs %
88.92%
Holding
82
New
22
Increased
15
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$19.3M
2
TSLA icon
Tesla
TSLA
+$17M
3
USFD icon
US Foods
USFD
+$12.2M
4
FOLD
Amicus Therapeutics
FOLD
+$8.74M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.93M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$37.2M
2
MA icon
Mastercard
MA
+$18.9M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$14.2M
4
JPM icon
JPMorgan Chase
JPM
+$12.5M
5
DAL icon
Delta Air Lines
DAL
+$9.74M

Sector Composition

Rank Sector Weight
1 Consumer Staples 55.65%
2 Healthcare 23%
3 Consumer Discretionary 8.41%
4 Financials 1.55%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
51
DELISTED
Acceleron Pharma
XLRN
$3.4M 0.07%
+100,000
New +$3.25M
LCTX icon
52
Lineage Cell Therapeutics
LCTX
$264M
$3.35M 0.07%
1,465,383
– –
SAGE
53
CALL
DELISTED
Sage Therapeutics
SAGE
$3.01M 0.06%
+100,000
New +$3.33M
CLDX icon
54
Celldex Therapeutics
CLDX
$2.94B
$2.96M 0.06%
45,000
– –
IRWD icon
55
Ironwood Pharmaceuticals
IRWD
$586M
$2.84M 0.06%
258,954
– –
ONCE
56
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$2.56M 0.05%
+50,000
New +$2.14M
ISEE
57
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.55M 0.05%
+50,000
New +$2.48M
GBT
58
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.07M 0.04%
+125,000
New +$2.52M
AGEN
59
CALL
Agenus
AGEN
$276M
$2.02M 0.04%
25,475
– –
JUNO
60
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.92M 0.04%
50,000
-50,000
-50% -$2.08M
SRPT icon
61
CALL
Sarepta Therapeutics
SRPT
$1.64B
$1.91M 0.04%
100,000
-100,000
-50% -$1.85M
DMTX
62
DELISTED
Dimension Therapeutics, Inc
DMTX
$1.65M 0.03%
275,000
– –
CEMP
63
DELISTED
Cempra, Inc.
CEMP
$1.65M 0.03%
+100,000
New +$1.76M
RGNX icon
64
Regenxbio
RGNX
$616M
$1.6M 0.03%
200,000
+40,000
+25% +$444K
AEGR
65
DELISTED
Aegerion Pharmaceuticals
AEGR
$1.49M 0.03%
+1,000,000
New +$2.29M
IBRX icon
66
ImmunityBio
IBRX
$7.15B
$1.4M 0.03%
225,000
– –
CERE
67
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$400K 0.01%
1,024,020
– –
IMDX
68
Insight Molecular Diagnostics
IMDX
$141M
$228K ﹤0.01%
3,205
– –
CLCD
69
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$46K ﹤0.01%
5,575
– –
AAPL icon
70
CALL
Apple
AAPL
$4.97T
– –
-1,600,000
Closed -$43.6M
AGIO icon
71
CALL
Agios Pharmaceuticals
AGIO
$2.08B
– –
-200,000
Closed -$8.12M
C icon
72
CALL
Citigroup
C
$213B
– –
-500,000
Closed -$20.9M
DAL icon
73
Delta Air Lines
DAL
$56.7B
– –
-200,000
Closed -$9.74M
GLPI icon
74
Gaming and Leisure Properties
GLPI
$13B
– –
-70,000
Closed -$2.1M
IONS icon
75
Ionis Pharmaceuticals
IONS
$8.93B
– –
-350,000
Closed -$14.2M
1 2
3
4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2016 Portfolio in Review

As of Q2 2016, Artal Group held 82 positions worth $4.84B, down 5.5% from $5.13B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Artal Group's Q2 2016 filing shows 22 new, 15 increased, 12 reduced and 13 closed positions. Its largest new stake was Regeneron Pharmaceuticals: 50,000 shares worth $17.5M. The largest sale was Celgene Corp, an estimated $37.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 56% of assets, down from 58% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Artal Group's largest Q2 2016 buy was Regeneron Pharmaceuticals: 50,000 shares worth $17.5M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q2 2016, an estimated $6.93M increase.
  • Artal Group's biggest Q2 2016 reduction was Nektar Therapeutics, cutting an estimated $8.94M.
  • Artal Group fully exited Celgene Corp in Q2 2016, selling an estimated $37.2M.
  • Artal Group's ten largest holdings make up 89% of its $4.84B portfolio in Q2 2016.
  • Artal Group opened 22 new positions and closed 13 in Q2 2016.
  • Artal Group's portfolio value fell 5.5% quarter-over-quarter to $4.84B.

Based on Artal Group's 13F filing for Q2 2016, filed 11 Aug 2016.